PD-L1 checkpoint inhibitor (Regeneron/Sanofi)

N/A

Report date: 2025/03/20 15:38:15

Base Information

Drug NamePD-L1 checkpoint inhibitor (Regeneron/Sanofi)
Drug Alias Nameanti-PD-L1 antibodies (Regeneron/Sanofi)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A